α2-adrenoreceptors profile modulation. 4. From antagonist to agonist behavior

Journal of Medicinal Chemistry

Volumn 51, Issue 14, 2008, Pages 4289-4299

  Gentili, Francesco ^a   Cardinaletti, Claudia ^a   Vesprini, Cristian ^a   Carrieri, Antonio ^b   Ghelfi, Francesca ^a   Farande, Aniket ^a   Giannella, Mario ^a   Piergentili, Alessandro ^a   Quaglia, Wilma ^a   Laurila, Jonne M ^c   Huhtinen, Anna ^c   Scheinin, Mika ^c   Pigini, Maria ^a  

^a UNIVERSITY OF CAMERINO   (Italy)

^b UNIVERSITY OF BARI   (Italy)

^c UNIVERSITY OF TURKU   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

2 [1 (2 ALLYLPHENOXY)ETHYL] 4,5 DIHYDRO 1H IMIDAZOLE; 2 [1 (2 CYCLOPENTYLPHENOXY)ETHYL] 4,5 DIHYDRO 1H IMIDAZOLE; 2 [1 (4,5 DIHYDRO 1H IMIDAZOL 2 YL)ETHOXY]BENZALDEHYDE OXIME; ALPHA 2 ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ALPHA 2A ADRENERGIC RECEPTOR; ALPHA 2B ADRENERGIC RECEPTOR; ALPHA 2C ADRENERGIC RECEPTOR; AROMATIC COMPOUND; BENZENE DERIVATIVE; CLONIDINE; LIGAND; NORADRENALIN; RECEPTOR SUBTYPE; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG BINDING SITE; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; NONHUMAN; PROTEIN DOMAIN; RECEPTOR UPREGULATION; STEREOSPECIFICITY; STRUCTURE ACTIVITY RELATION; ANIMAL; CHO CELL; CLASSIFICATION; CRICETULUS; DRUG ANTAGONISM; DRUG POTENTIATION; HAMSTER; MOUSE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; RAT;

ADRENERGIC ALPHA-AGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANIMALS; CHO CELLS; CRICETINAE; CRICETULUS; MAGNETIC RESONANCE SPECTROSCOPY; MICE; RATS; RECEPTORS, ADRENERGIC, ALPHA-2;

EID: 47749124559     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm800250z     Document Type: Article

References (37)

1. For part 3, see ref 26.
2. Pigini, M.; Quaglia, W. Adrenoceptors as targets in drug discovery: medicinal chemistry and therapeutical potential. Curr. Top. Med. Chem. 2007, 7, 127.
3. Gentili, F.; Pigini, M.; Piergentili, A.; Giannella, M. Agonists and antagonists targeting the different α2-adrenoceptor subtypes. Curr. Top. Med. Chem. 2007, 7, 163-186.
4. 2-adrenoceptors. J. Neurochem. 2001, 78, 685-693.
5. 2-adrenergic receptors. J. Pharmacol. Exp. Ther. 2000, 293, 1-7.
6. Kuusela, E.; Raekallio, M.; Anttila, M.; Falck, I.; Molsa, S.; Vainio, O. Clinical effects and pharmacokinetics of medetomidine and its enantiomers in dogs. J. Vet. Pharmacol. Ther. 2000, 23, 15-20.
7. Snapir, A.; Posti, J.; Kentala, E.; Koskenvuo, J.; Sundell, J.; Tuunanen, H.; Hakala, K.; Scheinin, H.; Knuuti, J.; Scheinin, M. Effects of low and high plasma concentrations of dexmedetomidine on myocardial perfusion and cardiac function in healthy male subjects. Anesthesiology 2006, 105, 902-910.
8. Scheinin, M.; Snapir, A. G-protein coupled receptors as cardiovascular drug targets. In G-Protein Coupled Receptors in Drug Discovery; Lundstrom, K. H., Chiu, M. L. Eds.; Taylor & Francis: London, 2006; pp 37-51.
9. (a) Gilsbach, R.; Brede, M.; Beetz, N.; Moura, E.; Muthig, V.; Gerstner, C.; Barreto, F.; Neubauer, S.; Vieira-Coelho, M. A.; Hein, L. Heterozygous alpha 2C-adrenoreceptor-deficient mice develop heart failure after transverse aortic constriction. Cardiovasc. Res. 2007, 75, 728-737.
10. (b) Regitz-Zagrosek, V.; Hocher, B.; Bettmann, M.; Brede, M.; Hadamek, K.; Gerstner, C.; Lehmkuhl, H. B.; Hetzer, R.; Hein, L. Alpha 2C-adrenoceptor polymorphism is associated with improved event-free survival in patients with dilated cardiomyopathy. Eur. Heart J. 2006, 27, 454-459.
11. (c) Brede, M.; Wiesmann, F.; Jahns, R.; Hadamek, K.; Arnolt, C.; Neubauer, S.; Lohse, M. J.; Hein, L. Feedback inhibition of catecholamine release by two different alpha2-adrenoceptor subtypes prevents progression of heart failure. Circulation 2002, 106, 2491-2496.
12. Gentili, F.; Bousquet, P.; Brasili, L.; Caretto, M.; Carrieri, A.; Dontenwill, M.; Giannella, M.; Marucci, G.; Perfumi, M.; Piergentili, A.; Quaglia, W.; Rascente, C.; Pigini, M. α2-Adrenoreceptors profile modulation and high antinociceptive activity of (S)-(-)-2-[1-(biphenyl-2- yloxy)ethyl]-4,5-dihydro-1H-imidazole. J. Med. Chem. 2002, 45, 32-40.
13. 2C- subtype. J. Med. Chem. 2004, 47, 6160-6173.
14. 2-adrenergic receptor involves disruption of an ionic lock between the cytoplasmic ends of transmembrane segments 3 and 6. J. Biol. Chem. 2001, 276, 29171-29177.
15. Melloni, P.; Della Torre, A.; Meroni, M.; Pevarello, P.; Varasi, M.; Bonsignori, A.; Cini, M.; Vaghi, F.; Dostert, P. Synthesis of new fenmetazole analogues with potential mixed α2-adrenergic antagonistic activity and noradrenaline-uptake inhibiting properties. Eur. J. Med. Chem. 1991, 26, 207-213.
16. Dabiré, H. Idazoxan: a novel pharmacological tool for the study of α2-adrenoceptors. J. Pharmacol. 1986, 17, 113-118.
17. 2- adrenergic receptor subtypes. J. Pharmacol. Exp. Ther. 1994, 268, 1362-1367.
18. Picciola, G.; Carissimi, M.; Ravenna, F.; Gentili, P.; Carenini, G. Cyclohexylphenoxy amidoximes and imidazolines with antidepressive and α-adrenergic activity. Arzneim.-Forsch. 1979, 29, 729-738.
19. Minutolo, F.; Bertini, S.; Papi, C.; Carlson, K. E.; Katzenellenbogen, J. A.; Macchia, M. Salicylaldoxime moiety as a phenolic "A-ring" substitute in estrogen receptor ligands. 1. J. Med. Chem. 2002, 44, 4288-4291.
20. Mitsunobu, O. The use of diethyl azodicarboxylate and triphenylphosphine in synthesis and transformation of natural products. Synthesis 1981, 1, 1-28.
21. Voronina, T. A.; Glozman, O. M.; Orlova, E. K.; Troitskaya, V. S.; Nerobkova, L. N.; Rakhmankulova, I. Kh.; Zagorevskii, V. A. Synthesis and psychotropic activity of 2-phenoxypropionic oxamidines and their analogs. Khim. Farm. Z. 1984, 18, 1309-1313,
22. Chem. Abstr. 102, 184774.
23. Bondesson, G.; Högberg, T.; Misiorny, A.; Stjernström, N. E. Potential hypolipidemic agents. XIV. Synthesis and plasma lipid-lowering properties of substituted biphenyls, diphenyl ethers and benzofurans related to ethyl 2-(4-dibenzofuranyloxy)-2-methylpropionate. Acta Pharm. Suec. 1976, 13, 97-106.
24. 3]-isotopomers. Org. Biomol. Chem. 2004, 2, 2624-2629.
25. 2-Adrenoceptor regulation of adenylyl cyclase in CHO cells: dependence on receptor density, receptor subtype and current activity of adenylyl cyclase. Eur. J. Pharmacol. 1997, 335, 53-63.
26. Olli-Lähdesmäki, T.; Tiger, M.; Vainio, M.; Scheinin, M.; Kallio, J. Ligand-induced α2-adrenoceptor endocytosis: relationship to Gi protein activation. Biochem. Biophys. Res. Commun. 2004, 321, 226-233.
27. 3H]RX821002 as radioligands. Biochim. Biophys. Acta 1995, 1266, 207-214.
28. 50) of an enzymatic reaction. Biochem. Pharmacol. 1973, 22, 3099-3108.
29. 2C-subtype selective agonist. J. Med. Chem. 2007, 50, 3964-3968, and references therein.
30. 2-adrenoceptor subtypes with cytosensor microphysiometry. Eur. J. Pharmacol. 1999, 385, 247-253.
31. Arunlakshana, O.; Schild, H. O. Some quantitative uses of drug antagonists. Br. J. Pharmacol. Chemother. 1959, 14, 48-58.
32. Macchia, B.; Balsamo, A.; Breschi, M. C.; Chiellini, G.; Macchia, M.; Martinelli, A.; Martini, C.; Nardini, C.; Nencetti, S.; Rossello, A.; Scatizzi, R. The [(methyloxy)imino]methyl moiety as a bioisoster of aryl. A novel class of completely aliphatic β-adrenergic receptor antagonists. J. Med. Chem. 1994, 37, 1518-1525.
33. 2A-adrenoceptor gene. Eur. J. Pharmacol. 2006, 529, 105-113.
34. 2O) donor atom set. Tetrahedron Lett. 1989, 1609-1612.
35. Bradford, M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976, 72, 248-254.
36. Eglen, R. M.; Hudson, A. L.; Kendall, D. A.; Nutt, D. J.; Morgan, N. G.; Wilson, V. G.; Dillon, M. P. "Seeing through a glass darkly": casting light on imidazoline "I" sites. Trends Pharmacol. Sci. 1998, 19, 381-390.
37. McMartin, C.; Bohacek, R. S. QXP: powerful, rapid computer algorithms for structure-based drug design. J. Comput.-Aided Mol. Des. 1997, 11, 333-344.